CoChat

Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

Open access
Picatoste, Belén, Ramírez, Elisa, Caro-Vadillo, Alicia, Iborra, Cristian, Egido, Jesús, Tuñón, José, Lorenzo, Óscar · 2013 · PLoS ONE
Cited by 101

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Myocardial fibrosis is a key process in diabetic cardiomyopathy. However, their underlying mechanisms have not been elucidated, leading to a lack of therapy. The glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, reduces hyperglycemia but may also trigger direct effects on the heart. METHODS: Goto-Kakizaki (GK) rats developed type-II diabetes and received sitagliptin, an anti-hyperglycemic drug (metformin) or vehicle (n=10, each). After cardiac structure and function assessment, plasma and left ventricles were isolated for biochemical studies. Cultured cardiomyocytes and fibroblasts were used for in vitro assays. RESULTS: Untreated GK rats exhibited hyperglycemia, hyperlipidemia, plasma GLP-1 decrease, and cardiac cell-death, hypertrophy, fibrosis and prolonged deceleration time. Moreover, cardiac pro-apoptotic/necrotic, hypertrophic and fibrotic factors were up-regulated. Importantly, both sitagliptin and metformin lessened all these parameters. In cultured cardiomyocytes and cardiac fibroblasts, high-concentration of palmitate or glucose induced cell-death, hypertrophy and fibrosis. Interestingly, GLP-1 and its insulinotropic-inactive metabolite, GLP-1(9-36), alleviated these responses. In addition, despite a specific GLP-1 receptor was only detected in cardiomyocytes, GLP-1 isoforms attenuated the pro-fibrotic expression in cardiomyocytes and fibroblasts. In addition, GLP-1 receptor signalling may be linked to PPARδ activation, and metformin may also exhibit anti-apoptotic/necrotic and anti-fibrotic direct effects in cardiac cells. CONCLUSIONS: Sitagliptin, via GLP-1 stabilization, promoted cardioprotection in type-II diabetic hearts primarily by limiting hyperglycemia e hyperlipidemia. However, GLP-1 and GLP-1(9-36) promoted survival and anti-hypertrophic/fibrotic effects on cultured cardiac cells, suggesting cell-autonomous cardioprotective actions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0078330

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 44

  1. S Chen, 2000, Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors, J Mol Cell Cardiol, 32, 1621, 10.1006/jmcc.2000.1197 · DOI
  2. K Mizushige, 2000, Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model, Circulation, 101, 899, 10.1161/01.CIR.101.8.899 · DOI · Paper page
  3. DJ Drucker, 2007, Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action, Diabetes Care, 30, 1335, 10.2337/dc07-0228 · DOI · Paper page
  4. S Mudaliar, 2012, The incretin hormones: from scientific discovery to practical therapeutics, Diabetologia, 55, 1865, 10.1007/s00125-012-2561-x · DOI
  5. H Hui, 2010, Glucagon like peptide-1-directed human embryonic stem cells differentiation into insulin-producing cells via hedgehog, cAMP, and PI3K pathways, Pancreas, 39, 315, 10.1097/MPA.0b013e3181bc30dd · DOI
  6. DA Glauser, 2007, Transcriptional response of pancreatic beta cells to metabolic stimulation: large scale identification of immediate-early and secondary response genes, BMC Mol Biol, 8, 54, 10.1186/1471-2199-8-54 · DOI
  7. K-D Wagner, 2010, Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions, Pharmacol Ther, 125, 423, 10.1016/j.pharmthera.2009.12.001 · DOI · Paper page
  8. H Zhang, 2007, PPARbeta/delta activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts, Arch Biochem Biophys, 460, 25, 10.1016/j.abb.2007.01.028 · DOI
  9. C-G Ostenson, 2007, Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans, Diabetes Obes Metab, 9, 180, 10.1111/j.1463-1326.2007.00787.x · DOI
  10. A Tahara, 2009, Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors, Pharmacol Rep, 61, 899, 10.1016/S1734-1140(09)70147-1 · DOI
  11. C Orskov, 1987, Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), Scand J Clin Lab Invest, 47, 165, 10.3109/00365518709168885 · DOI
  12. EM Escudero, 2004, Echocardiographic assessment of left ventricular midwall mechanics in spontaneously hypertensive rats, Eur J Echocardiogr, 5, 169, 10.1016/j.euje.2003.11.004 · DOI
  13. S Ravassa, 2011, Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes, Am J Physiol Heart Circ Physiol, 300, H1361, 10.1152/ajpheart.00885.2010 · DOI · Paper page
  14. R Martín, 2012, DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy, PLOS ONE, 7, e41545, 10.1371/journal.pone.0041545 · DOI
  15. F Strutz, 1995, Identification and characterization of a fibroblast marker: FSP1, J Cell Biol, 130, 393, 10.1083/jcb.130.2.393 · DOI · Paper page
  16. DLM Hickson-Bick, 2002, Palmitate-induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS, Am J Physiol Heart Circ Physiol, 282, H656, 10.1152/ajpheart.00726.2001 · DOI · Paper page
  17. Y Ishibashi, 2011, Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells, Horm Metab Res, 43, 731, 10.1055/s-0031-1284383 · DOI
  18. S Ares-Carrasco, 2012, Proteome changes in the myocardium of experimental chronic diabetes and hypertension: Role of PPARα in the associated hypertrophy, J Proteomics, 75, 1816, 10.1016/j.jprot.2011.12.023 · DOI
  19. S Dhillon, 2010, Sitagliptin: a review of its use in the management of type 2 diabetes mellitus, Drugs, 70, 489, 10.2165/11203790-000000000-00000 · DOI
  20. Y Ye, 2010, The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA, Am J Physiol Heart Circ Physiol, 298, H1454, 10.1152/ajpheart.00867.2009 · DOI · Paper page
  21. P Anagnostis, 2011, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control, Diabetes Obes Metab, 13, 302, 10.1111/j.1463-1326.2010.01345.x · DOI · Paper page
  22. M Rajesh, 2010, Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, J Am Coll Cardiol, 56, 2115, 10.1016/j.jacc.2010.07.033 · DOI · Paper page
  23. S Ares-Carrasco, 2009, Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes, Am J Physiol Heart Circ Physiol, 297, H2109, 10.1152/ajpheart.00157.2009 · DOI
  24. A D’Souza, 2011, Left Ventricle Structural Remodelling in the Prediabetic Goto-Kakizaki Rat, Exp Physiol, 96, 875, 10.1113/expphysiol.2011.058271 · DOI
  25. BH Lorell, 2000, Left ventricular hypertrophy: pathogenesis, detection, and prognosis, Circulation, 102, 470, 10.1161/01.CIR.102.4.470 · DOI · Paper page
  26. TJ Regan, 1983, Congestive heart failure in the diabetic, Annu Rev Med, 34, 161, 10.1146/annurev.me.34.020183.001113 · DOI · Paper page
  27. M Lenski, 2011, Effects of DPP-4 inhibition on cardiac metabolism and function in mice, J Mol Cell Cardiol, 51, 906, 10.1016/j.yjmcc.2011.08.001 · DOI
  28. M Rendell, 2012, Alogliptin benzoate for the treatment of type 2 diabetes, Expert Opin Pharmacother, 13, 553, 10.1517/14656566.2012.656088 · DOI
  29. J Rosenstock, 2008, Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes, Diabetes Obes Metab, 10, 376, 10.1111/j.1463-1326.2008.00876.x · DOI · Paper page
  30. G Mellitzer, 2011, Enteroendocrine cells and lipid absorption, Curr Opin Lipidol, 22, 171, 10.1097/MOL.0b013e32834622a2 · DOI
  31. M Cobble, 2012, Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus, 10.1186/1758-5996-4-8 · DOI
  32. M Sauvé, 2010, Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice, Diabetes, 59, 1063, 10.2337/db09-0955 · DOI · Paper page
  33. Y Ishibashi, 2012, Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A, Microvasc Res, 84, 395, 10.1016/j.mvr.2012.06.008 · DOI
  34. A Mima, 2012, Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes, Diabetes, 61, 2967, 10.2337/db11-1824 · DOI · Paper page
  35. PA Read, 2010, DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease, Circ Cardiovasc Imaging, 3, 195, 10.1161/CIRCIMAGING.109.899377 · DOI · Paper page
  36. R Gros, 2003, Cardiac function in mice lacking the glucagon-like peptide-1 receptor, Endocrinology, 144, 2242, 10.1210/en.2003-0007 · DOI · Paper page
  37. E Tomas, 2010, Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis, Trends Endocrinol Metab, 21, 59, 10.1016/j.tem.2009.11.007 · DOI · Paper page
  38. X-F Wang, 2011, Beneficial effects of metformin on primary cardiomyocytes via activation of adenosine monophosphate-activated protein kinase, Chin Med J (Engl), 124, 1876
  39. H Xiao, 2010, Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway, Cardiovasc Res, 87, 504, 10.1093/cvr/cvq066 · DOI · Paper page
  40. H Oeseburg, 2010, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A, Arterioscler Thromb Vasc Biol, 30, 1407, 10.1161/ATVBAHA.110.206425 · DOI · Paper page
  41. KA Burns, 2007, Modulation of PPAR activity via phosphorylation, Biochim Biophys Acta, 1771, 952, 10.1016/j.bbalip.2007.04.018 · DOI · Paper page
  42. N Wagner, 2009, Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin, Cardiovasc Res, 83, 61, 10.1093/cvr/cvp106 · DOI
  43. SC Fan, 2010, The decreased expression of peroxisome proliferator-activated receptors delta (PPARdelta) is reversed by digoxin in the heart of diabetic rats, Horm Metab Res, 42, 637, 10.1055/s-0030-1253373 · doi:10.1055/s-0030-1253373
  44. HJ Kim, 2009, Peroxisome proliferator-activated receptor {delta} regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/Smad3, Circ Res, 105, 16, 10.1161/CIRCRESAHA.108.189159 · DOI

Cited by

See all 101

Metadata

Authors
Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó.
Venue
PLoS ONE
Published
2013-10-21
Volume
8
Issue
10
Pages
e78330
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2001535323
Cited by
101
References
10
FWCI
8.05
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. https://app.cochat.ai/papers/10.1371/journal.pone.0078330
The paper
Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó. (2013). Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. PLoS ONE. https://doi.org/10.1371/journal.pone.0078330

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.